This study aims to evaluate the cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib-fulvestrant for treating advanced HR+/HER2-breast cancer patients with PIK3CA mutations from both United States (U.S.)and Chinese healthcare system perspectives. This evidence concerns the gene ERBB2 and breast cancer.